U.S. Markets close in 1 hr 16 mins
  • S&P 500

    +7.25 (+0.16%)
  • Dow 30

    -56.26 (-0.16%)
  • Nasdaq

    +110.14 (+0.75%)
  • Russell 2000

    +26.70 (+1.22%)
  • Crude Oil

    +0.73 (+1.02%)
  • Gold

    -2.70 (-0.15%)
  • Silver

    +0.23 (+0.94%)

    +0.0006 (+0.0473%)
  • 10-Yr Bond

    +0.0270 (+2.19%)
  • Vix

    -1.17 (-6.04%)

    +0.0014 (+0.1014%)

    +0.2490 (+0.2268%)

    +2,274.77 (+6.01%)
  • CMC Crypto 200

    +6.48 (+0.70%)
  • FTSE 100

    +20.55 (+0.29%)
  • Nikkei 225

    -388.56 (-1.39%)

Waters (WAT) Expands Reach to Scientists Via Latest Launch

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Waters Corporation WAT continues to make advances to bolster presence in the pharmaceutical industry on the back of robust technologies.

This is evident from the company’s latest launch of the liquid chromatography system named Waters Arc Premier System, which is optimized for chromatographic separations on 2.5-3.5 micron columns.

The system features the new MaxPeak High Performance Surface technology, which offers increased analyte recovery for accurate and precise quantification, higher detector sensitivity, improvement in system-to-system and user-to-user reproducibility as well as savings by eliminating system passivation and column conditioning along with greater productivity and profitability.

The Arc Premier System helps scientists in developing methods for stability testing, impurity profiling, and product release data compliant by delivering reproducibility and repeatability.

Waters Corporation Price and Consensus

Waters Corporation Price and Consensus
Waters Corporation Price and Consensus

Waters Corporation price-consensus-chart | Waters Corporation Quote

Hence, the move is likely to expand the company’s reach to scientists in the pharmaceutical space. This in turn will drive the performance of its pharmaceutical segment, from which it generated 59% of total revenues for fiscal first-quarter 2021.

Further, the latest move will boost Waters’ presence in the growing global liquid chromatography instruments market, which, per a report by The Expresswire mentioned in MarketWatch, is likely to hit $5.5 billion by 2026, progressing at a CAGR of 4.1% between 2021 and 2026.

Expanding Product portfolio

The latest move bodes well for Waters’ strong efforts to expand the product portfolio consisting chromatography consumables and columns, mass spectrometry systems, laboratory automation, integrated solutions and others.

Apart from the Arc Premier System launch, the company recently unveiled a high-resolution mass spectrometer — SELECT SERIES Multi Reflecting Time-of-Flight technology — with desorption electrospray ionization and matrix-assisted laser desorption ionization imaging sources for applications in pharmaceutical, biomedical, natural products, and materials research.

Additionally, early this year, the company launched ACQUITY PREMIER liquid chromatography solution, which features the High Performance Surface technology to deliver better qualitative and quantitative analytical results.

Also, Waters launched its time-of-flight mass spectrometer, ACQUITY RDa Detector, which features SmartMS suitable for small molecule analysis for pharmaceutical, academic, food as well as forensics applications.

Moreover, the company introduced Otto SPEcialist Positive Pressure Manifold, which provides more reliability and reproducibility of solid phase extraction with greater efficiency — ideal for various pharmaceutical, biopharmaceutical food and beverage as well as environmental applications.

Waters’ strategic partnerships are continuing to bolster its portfolio. It recently joined forces with Genovis for developing automated biotherapeutic characterization workflows, focusing on rapid and consistent characterization of critical quality attributes of monoclonal antibodies as well as other protein-based drugs in bioprocess development, formulation, stability testing, and quality control.

The company also collaborated with TetraScience to offer unparalleled insights into chromatography data by Empower Data Science Link powered by the latter.

We believe that the above endeavours will continue to benefit Waters in gaining strong momentum in various end markets.

Zacks Rank & Stocks to Consider

Currently, Waters carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader technology sector include Digital Turbine APPS, MACOM Technology Solutions Holdings MTSI and Advanced Micro Devices AMD. While Digital Turbine sports a Zacks Rank #1 (Strong Buy), MACOM and Advanced Micro Devices carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Long-term earnings growth rates for Digital Turbine, MACOM and Advanced Micro Devices are currently projected at 50%, 37% and 35.01% respectively.

Time to Invest in Legal Marijuana

If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.

After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%

You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.

Today, Download Marijuana Moneymakers FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report

Waters Corporation (WAT) : Free Stock Analysis Report

MACOM Technology Solutions Holdings, Inc. (MTSI) : Free Stock Analysis Report

Digital Turbine, Inc. (APPS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research